Counterfeit Cancer Drugs in India: A Detailed Investigation

This report unravels the alarming intersection of a rapidly growing cancer population and the availability of counterfeit expensive cancer drugs in India. The narrative focuses on the plight of a liver cancer patient in Punjab and the larger counterfeit drug market, specifically targeting Keytruda, a high-value cancer drug manufactured by Merck & Co.

Keytruda and the Black Market

• Patient's Experience: A 56-year-old woman began treatment for liver cancer at PGIMER near Chandigarh, where doctors recommended Keytruda. 
  • The official market price for Keytruda is over Rs 1.5 lakh for a 100 mg vial.
  • The family purchased 12 vials at a discount for approximately Rs 16 lakh, only to find they were counterfeit, filled with antifungal medication.
• Extent of the Counterfeit Market: Investigations reveal a black market operating from Nepal to Mexico, influencing the supply chain of cancer drugs like Keytruda. 
  • Counterfeiting of medicines is a common problem in India, affecting drug types from antibiotics to antacids.
  • The Indian Express investigation found batch numbers of counterfeit Keytruda that matched those administered to patients in top Delhi hospitals.

Investigation Details

• Operation Details: The counterfeit operation involved collecting empty Keytruda vials, refilling them with other substances, and selling them at reduced prices. 
  • Counterfeit vials were sold for Rs 90,000 per 100-mg vial, a 40% discount from the market price.
• Key Individuals and Arrests: The investigation led to the arrest of a "distributor" Neeraj Chauhan, along with several pharmacists, for their roles in the supply chain of counterfeit drugs. 
  • Pharmacists at prominent cancer hospitals were intercepted carrying semi-filled vials in ordinary luggage.
  • Key arrests include Neeraj Chauhan, Komal Tiwari, and Abhinay, among others, involved in the distribution and handling of counterfeit drugs.

Hospital Loopholes and Responses

• Vulnerability of Hospital Systems:
  • Hospitals lacked a formal process for counting disposed vials, enabling diversion at the point of disposal.
  • Despite surveillance measures, critical loopholes in drug handling and disposal were exploited by the counterfeit network.
• Hospital Measures: Hospitals like RGCIRC and Venkateshwar Hospital have since implemented stricter protocols to prevent future occurrences. 
  • Changes include prepared drug mixing in the presence of patient attendants, CCTV surveillance, and documented disposal processes.

Impacts and Conclusions

• Patient Impact: The counterfeit drug operation has severe repercussions on patients, financially and health-wise, as evident in tragic cases like the 38-year-old woman from Bihar. 
  • Patients, desperate for affordable treatment, are often unwittingly drawn into purchasing counterfeit drugs through informal channels.
• Law Enforcement and Regulatory Response: This investigation highlights the urgent need for stronger oversight and protection mechanisms to safeguard vulnerable patients seeking cancer treatment. 
  • Authorities continue to track and dismantle counterfeit drug networks to protect critical patients.